Facebook-f X-twitter Linkedin-in Instagram Podcast

Podcasts

Episode 51 | Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy

In this episode, Prof Tom John, Prof Georgina Long AO, and Prof Ken O’Byrne delve into technological advances spurred by COVID-19 vaccine development, promising results from recent melanoma and lung cancer vaccine trials, and the potential for personalised neoantigen mRNA vaccines.

Episode Summary

In this episode of ‘Conversations in Lung Cancer Research, the experts delve into technological advances spurred by COVID-19 vaccine development, promising results from recent melanoma and lung cancer vaccine trials, and the potential for personalised neoantigen mRNA vaccines.

They also discuss historical challenges in vaccine efficacy and the promising future of immunotherapy and cancer vaccines, including patient perspectives and the logistics of rapid vaccine production and distribution.

 Show Hosts

  • Prof Tom John, medical oncologist from the Peter MacCallum Cancer Centre
  • Prof Ken O’Byrne, medical oncologist and clinical scientist at the Princess Alexandra Hospital and Queensland University of Technology
  • Prof Georgina Long AO, the medical director of the Melanoma Institute of Australia and co-recipient of the 2024 Australian of the Year

 

Prof Tom John Prof Georgina Long AO Prof Ken O'Byrne

Play Episode 51 | Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy

Download Audio File
Listen on Apple
Listen on Spotify

More Podcasts

50 – The Role of Liquid Biopsy in Modern Oncology
In this episode, Dr. Malinda Itchins, Dr. Annie Wong, and A/Prof Steven Kao discuss the concept of liquid biopsy, its advantages and limitations, and its
Headshots of A/Prof Surein Arulananda, A/Prof Mel Moore, Dr. Malinda Itchins. 49 Exploring EGFR Exon 20 Insertion Mutations
49 – Exploring EGFR Exon 20 Insertion Mutations
In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into
Conversations in Lung Cancer Research - Michael Boyer
48 – A Conversation with Prof. Michael Boyer
In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and
Text Conversations in Lung Cancer on Blue background and TOGA logo
47 – Introducing Conversations in Lung Cancer Research
In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'
46 – Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy
Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
45 – The Case For IO in Early-Stage NSCLC in a Once in a Lifetime World
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

Facebook-f X-twitter Linkedin-in Instagram Podcast
TOGA
Quicklinks
TOGA is an ACNC Registered Charity

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.

Copyright © 2025 TOGA – Thoracic Oncology Group Australasia. No part of this site may be reproduced without our written permission.